Status:
COMPLETED
Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hepatitis C, Chronic
Genotype 1
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of this study is to evaluate the impact of chronic hepatitis C (CHC), and the treatment thereof with peginterferon alpha-2b (PEG) and ribavirin (RBV) according to standard clinic...
Detailed Description
As widely shown in previous reports Hepatitis C Virus (HCV) patients commonly experience fatigue, anxiety, and depression. These symptoms negatively affect patients' functional health, ability to work...
Eligibility Criteria
Inclusion
- Participants diagnosed with chronic hepatitis C (CHC)
- Participants with HCV genotype 1
- Participants who, at the time of the study, are referred to the Hospital Pharmacy Service to begin treatment with PEG and RBV for 48 weeks
- Available to understand and to give Informed Consent
Exclusion
- \- Participants co-infected with Human Immunodeficiency Virus (HIV) or Hepatitis B Virus (HBV)
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT00863109
Start Date
April 1 2009
End Date
May 1 2013
Last Update
April 7 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.